1	Title page
2	
3	
4	Full title: Clinical characteristics and outcomes of pulmonary haemorrhage in
5	leptospirosis: A retrospective cohort study from Sri Lanka
6	
7	Short title: Characteristics and outcome of pulmonary haemorrhage in leptospirosis
8	
9 10	
10	Pramith Ruwanpathirana ^{1¶*} , Nilanka Perera ^{2¶} , Roshan Rambukwella ^{3¶} , Dilshan Priyankara ^{4¶}
12	
13	1 – Professorial unit in medicine, National Hospital of Sri Lanka, Colombo, Sri Lanka
14	2 – Department of Medicine, Faculty of Medical Sciences, University of Sri
15	Jayewardenepura, Nugegoda, Sri Lanka
16	3 - Provincial Director of Health Services, Central Province, Kandy, Sri Lanka
17	4 – Medical intensive care unit, National Hospital of Sri Lanka, Colombo, Sri Lanka
18	
19 20	* Corresponding author – pramithrp@gmail.com
20 21	Corresponding author – <u>pranntnip@gman.com</u>
22	
23	
24	
25	
26	Authors' contributions
27	DP conceptualized, designed, and conducted the study. RH and PR analysed the data. PR
28	drafted the initial manuscript. NP, DP, and RH critically revised the manuscript. All authors
29	have contributed significantly to the study.

30

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31

Abstract

32 Background

33 Leptospirosis, a tropical, spirochaetal infection presents as an acute febrile illness with organ

- 34 injury. There is a paucity of data on clinical characteristics and treatment for Leptospirosis
- 35 Pulmonary Haemorrhage Syndrome (LPHS).

36

37 Methodology and principal findings

A retrospective cohort study was conducted including all patients with LPHS treated in the medical Intensive Care Unit (ICU), at National Hospital Sri Lanka from 2019 to 2022 to describe the clinical characteristics and factors related to poor outcomes. Survival of patients who received different treatment modalities for LPHS was compared.

42

43 Seventy patients were studied with a mean age of 42.69 ± 27.84 years and 61 (87.1%) males. 44 Forty-nine (70%) were mechanically ventilated and 16 (22.9%) died. Higher heart rate, higher lactate, lower pH on admission to ICU, and requirement of blood product transfusion were 45 associated with increased mortality. Patients were treated with plasmapheresis (PLEX), 46 intranasal desmopressin (DDAVP), and intravenous steroids alone or in combination as the 47 specific treatment for LPHS. Seven (10%) patients were treated with PLEX alone, 13 (18.6%) 48 with PLEX + DDAVP, 46 (65.7%) with PLEX + DDAVP + steroids, and 4(5.7%) were treated with 49 steroids alone. All patients who received the PLEX and DDAVP combination survived. There 50 were 11 (23.9%) deaths in the PLEX+ DDAVP + steroids group, 3 (49.2%) in the PLEX alone 51 group, and 2 (50%) in the steroids alone group. Mortality was least when PLEX was done for 52 53 3 days. Twenty-five (35.7%) patients developed hospital-acquired infections and risk factors 54 were mechanical ventilation and longer ICU stay.

55

56 Conclusions

- 57 The presence of tachycardia, acidosis, and high lactate predicted death in LPHS. PLEX and
- 58 DDAVP combination had better survival than other treatments alone or in combination for
- 59 LPHS. Randomized clinical trials are urgently needed to identify the role of PLEX and DDAVP
- 60 in treating LPHS.
- 61

62 Keywords:

- 63
- 64 Leptospirosis, Leptospirosis pulmonary haemorrhage syndrome, plasmapheresis,
- 65 desmopressin, treatment

66 Author Summary

67 Leptospirosis, a tropical infection causes multiple organ injury. Bleeding into the lungs (pulmonary haemorrhage) in leptospirosis is poorly studied. There is no established treatment 68 for pulmonary haemorrhage in leptospirosis (LPHS). A large cohort of LPHS patients treated 69 in a medical ICU in Sri Lanka was studied to identify clinical characteristics and outcomes. The 70 71 presence of higher heart rate, high lactate, lower pH, need for blood product, and intravenous tranexamic acid were identified as risk factors for death. We compared different treatment 72 modalities used for the treatment of LPHS. In addition to standard treatment with antibiotics 73 and supportive care, a combination of steroids, plasma exchange (PLEX), and intranasal 74 desmopressin (DDAVP) were used to treat LPHS. Mortality was least when patients were 75 treated with DDAVP + PLEX. The optimum duration of PLEX was 3 days. Clinical trials are 76 77 urgently needed to identify the benefit of PLEX and DDAVP in the treatment of LPHS.

79 Introduction

Leptospirosis, a zoonotic spirochaetal infection caused by Leptospira interrogans, results in 80 58,900 deaths (95% CI 23,800–95,900) per annum, worldwide [1,2]. Presenting as an acute 81 fever, leptospirosis can have multi-organ involvement including, acute kidney injury, acute 82 liver injury, myocarditis, aseptic meningitis, and pulmonary haemorrhage. Leptospirosis is 83 classically described as a bi-phasic illness, although it is not always obvious. The initial 84 'leptospiraemic phase' lasts for three to nine days and manifests as a febrile illness with 85 86 severe myalgia, prostration, and conjunctival suffusion. In this phase, the spirochetes disseminate to the organs haematologically. This is followed by the 'immune phase', where 87 IgM against *Leptospira* appears and the organisms disappear from the blood [1]. This phase 88 is characterized by an immune response against the spirochetes residing in the organs such 89 90 as the liver, lung, kidney, heart, and brain. It is believed that the resulting inflammation leads 91 to the end-organ injury of the immune phase of leptospirosis[3].

Leptospirosis pulmonary haemorrhage syndrome (LPHS) is a poorly studied entity and it is 92 believed to occur in 20% - 70% [4] of patients with a mortality rate of 43%[5] to 55%[6], 93 occurring within the first week of illness[7,8]. Its pathogenesis is postulated to be due to the 94 direct alveolar damage [9] caused by the organism and/or host response against it [10]. 95 96 Autopsy studies of lungs in LPHS have detected *Leptospira* antigens in the pulmonary vascular endothelium [11, 12], linear deposition of immunoglobulins and complements in alveolar 97 surface [12], foci of interstitial inflammation with lymphocytes, plasma cells, and occasional 98 eosinophils [13]. Studies suggest the occurrence of a cytokine storm in severe leptospirosis 99 [14]. Pro-inflammatory mediators (IL-6, IL-8, and tumour necrosis factor-alpha (TNF ∞)) [3] 100 and elevated inducible nitric oxide activity in the lungs were found to be higher in patients 101 who developed LPHS, indicating an immune cell activation [15]. The exact pathogenesis of 102

LPHS is still debatable. Both direct alveolar-capillary damage by the spirochete and immunemediated damage are equally plausible. In the latter instance, the *Leptospira* antigens found in the lung specimens could be those found in the antigen-antibody complexes.

106

107 Treatment of LPHS is not well established due to paucity of evidence. Randomized controlled trials are minimal and most treatment strategies are based on case reports, observational 108 studies, or expert opinion. Steroids and plasma exchange (PLEX) have been tried as treatment 109 110 modalities considering the immune-based pathogenesis. Many case reports have demonstrated improvement of pulmonary manifestations following steroid treatment in 111 patients with LPHS although a randomized trial conducted in Thailand did not demonstrate a 112 benefit compared to standard of care [16]. The use of steroids was associated with 113 nosocomial infections. PLEX has been shown to significantly improve survival in observational 114 115 studies with the additional advantage of removing systemic toxic mediators. However, there 116 are no randomized trials supporting this observation. Desmopressin (DDAVP), a selective vasopressin V_2 agonist has been used in LPHS [17] based on its utility in treating bleeding 117 diathesis in haemophilia A and von Willebrand disease [18]. 118

119

Sri Lanka is endemic for leptospirosis, reporting many outbreaks with morbidity and mortality.
There is an urgent need to generate evidence in an attempt to improve mortality. High-dose
steroid therapy (intravenous methylprednisolone followed by oral prednisolone) is
recommended in the national guideline of Sri Lanka based on the available limited evidence
[19]. PLEX is widely used to treat LPHS in Sri Lanka due to its observed benefit.

125

We report an observational study on a large number of LPHS patients treated in the Medical Intensive Care Unit (MICU) of the National Hospital of Sri Lanka (NHSL). This is the first report comparing the outcome of multiple modalities of treatment such as steroids, PLEX, DDAVP, or their combinations. This study provides useful information to guide treatment and plan future clinical trials.

131

132 Methods

133 Study design and study participants

This retrospective cohort study was done to describe the clinical features, treatment, and disease outcomes of patients with leptospirosis who developed pulmonary haemorrhage. The study was carried out in the MICU, NHSL. All patients admitted to the study site from 1st January 2019 to 1st January 2022 with a microbiological or serological diagnosis of leptospirosis and LPHS were recruited to the study.

139

140 Ethical approval

Ethical approval was obtained from the Ethics Review Committee of the National Hospital of Sri Lanka. Consent was not obtained from participants as this was a retrospective study. Administrative approval from the Deputy Director of the National Hospital of Sri Lanka was obtained to collect anonymized patient details for publication in scientific journals.

145

146 Study procedure

The clinical details were retrospectively extracted from the medical records into a pre-formed
data extraction sheet. The socio-demographic details, pre-ICU admission clinical parameters,
clinical progression, and treatment given in the ICU were extracted from the medical records.

- 150 The definitions used to diagnose leptospirosis and its complications are given in Table 1. The
- 151 therapeutic decisions were completely under the treating physician's discretion. Patients
- 152 were followed up until discharge from the MICU to describe the outcome.
- 153

154 **Table 1: Definitions used in the study population**

Condition	Definition
Microbiologically diagnosed leptospirosis	• A positive polymerase chain reaction (PCR) for <i>Leptospira interrogans</i> DNA in the serum of the patient within the first 7 days of illness
Serologically diagnosed leptospirosis[19]	 A titer of ≥1:320 (cut-off recommended for Sri Lanka by the reference laboratory), OR
	 a four-fold rise in titre or seroconversion from acute and convalescent sera
	using a microscopic agglutination test
Pulmonary haemorrhage	 Development of haemoptysis (or blood-stained secretions from the endotracheal tube) AND
	 Hypoxia (SpO2 <94%) AND
	 Bilateral fluffy opacities in the lung parenchyma in chest radiograph OR
	HRCT evidence of pulmonary haemorrhage AND
	 Reduction of haemoglobin of more than 1g/dL within 48 hours
Myocarditis	Echocardiographic evidence of global hypokinesia AND
	 ECG changes including ST segment and T wave changes not confined to a vascular territory AND
	 Troponin I level higher than 3 times the upper limit of normal (ULN) in the absence of renal impairment and 5 times the ULN in patients with renal impairment

Acute kidney injury [20]	 Increase in serum creatinine by 0.3mg/dL or more within 48 hours or
	 Increase in serum creatinine to 1.5 times baseline or more within the last 7 days or
	 Urine output less than 0.5 mL/kg/h for 6 hours

Abbreviations: SpO₂; peripheral oxygen saturation, HRCT; high resolution computed tomography,
 ECG; electrocardiograph.

157

158 Statistical analysis

159 Socio-demographic variables, clinical parameters, complications, treatment, and outcomes were described using descriptive statistics. Percentages were used to describe categorical 160 161 data. Continuous variables were described using means with standard deviations (SD), and 162 medians with interquartile ranges (IQRs) for variables with a normal or skewed distribution respectively. Differences between categorical variables were assessed using the Chi-square 163 statistic or Fisher's exact test. Continuous variables with a normal distribution were compared 164 using student t-test or one-way ANOVA. Continuous variables with a skewed distribution were 165 166 compared using the Mann-Whitney U test or Kruskal-Wallis's test. Clinical, and laboratory findings and therapy were compared between patients who died and patients who made a 167 complete recovery. The development of hospital-acquired infection and the mortality of the 168 patients were compared between the groups who received different treatment modalities by 169 logistic and Cox regression analysis. 170

171

172 Results

A total of seventy patients with LPHS were managed in the MICU during the study period. The mean age was 42.69 (±13.92) years with 61 (87.1%) males. Leptospirosis diagnosis was confirmed by polymerase chain reaction in 24 (34.3%) and microscopic agglutination titer in 46 (65.7%). Mechanical ventilation was required for 49 (70%) patients and renal replacement

177	therapy (RRT) was performed in 43 (61.4%) patients with acute kidney injury. There were 16
178	(22.9%) deaths. Patients who succumbed to the illness had a higher heart rate, lower pH with
179	a lower base excess, and a higher serum lactate on admission to MICU than patients who
180	survived (Table 1). Patients who did not survive the illness, required mechanical ventilation,
181	blood product transfusion, and intravenous tranexamic acid than patients who survived.
182	Mortality was higher in patients who received steroids alone or in combination with other
183	treatments compared to patients who did not receive steroids (Table 2).

184 Table 2: Comparison of clinical and laboratory parameters among patients who died and

- 185 patients who survived in the study population
- 186

Parameter	Died n=16	Survived						
	_	n=54	p-value					
Clinical parameters at the time of admission to MICU								
Heart rate (bpm)	115.9(22.1)	100.5(17.7)	0.001					
SBP (mmHg)	108.1(24.5)	117.0(24.4)	0.289					
DBP (mmHg)	63.9(12.9)	68.5(13.4)	0.931					
MAP (mmHg)	78.7(15.8)	84.7(15.9)	0.556					
WBC (x10 ³ /µL) *	11.9(8.7 - 20.9)	15.4(9.6 - 18.4)	0.737					
Haemoglobin (g/dL)	10.8(2.1)	10.3(2.3)	0.554					
Platelet count (x10 ³ / μ L) *	30.5 (20.3 - 51.3)	33.5(21.0 - 69.0)	0.585					
CRP (mg/dL)	232.7 (86.7)	221.8 (89.4)	0.419					
AST (U/L) *	96.5 (67.3 - 230.5)	85.0(59.5 - 168.8)	0.275					
ALT (U/L) *	54.5 (39.5 - 128.7)	50.0 (34.0 - 95.8)	0.590					
INR*	1.2 (1.1 - 1.4)	1.1 (1.0 - 1.4)	0.138					
APTT (seconds)*	35.8 (32.0 - 39.7)	34.0 (28.2 - 40.1)	0.524					
Serum creatinine (mg/dL)	392.6 (192.42)	346.0 (159.2)	0.574					
Serum sodium (mmol/L) *	136.0 (132.3 - 137.8)	136.0 (132.8 -139.3)	0.533					
Serum potassium(mmol/L)*	4.4 (3.9 - 4.6)	3.9 (3.5 - 4.3)	0.089					
рН	7.2 (0.1)	7.3 (0.1)	0.019					
Base excess (mmol/L)	-9.1 (5.9)	-6.8 (5.9)	0.093					
Serum lactate (mmol/L) *	4.0 (2.6 - 6.3)	2.1 (1.6 - 3.9)	0.024					
Complications	1	· · · · · ·						
Myocarditis	13 (81.3%)	45 (83.3%)	0.846					

medRxiv preprint doi: https://doi.org/10.1101/2024.03.25.24304826; this version posted March 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY	4.0 International license .

16 (100.0%)	53 (98.1%)	0.584				
7 (43.8%)	18 (33.3%)	0.445				
	1	1				
16 (100.0%)	33 (61.1%)	0.003				
5 (3.0 - 7.0)	5 (3.0 - 9.0)	0.814				
3 (18.8%)	2 (3.7%)	0.04				
10 (62.5%)	33 (61.1%)	0.920				
9 (56.3%)	17 (31.5%)	0.072				
15 (93.8%)	45 (83.3%)	0.296				
2 (12.5%)	1 (1.9%)	0.065				
5 (31.3%)	3 (5.6%)	0.005				
5.5 (2.25 - 9.5)	6 (4 - 12.0)	0.279				
Specific treatment for LPHS						
16 (100.0%)	42 (77.8%)	0.038				
14 (87.5%)	52 (96.3%)	0.183				
11 (68.8%)	47 (87.0%)	0.088				
	7 (43.8%) 16 (100.0%) 5 (3.0 - 7.0) 3 (18.8%) 10 (62.5%) 9 (56.3%) 15 (93.8%) 2 (12.5%) 5 (31.3%) 5.5 (2.25 - 9.5) 16 (100.0%) 14 (87.5%)	7 (43.8%) 18 (33.3%) 16 (100.0%) 33 (61.1%) 5 (3.0 - 7.0) 5 (3.0 - 9.0) 3 (18.8%) 2 (3.7%) 10 (62.5%) 33 (61.1%) 9 (56.3%) 17 (31.5%) 15 (93.8%) 45 (83.3%) 2 (12.5%) 1 (1.9%) 5 (31.3%) 3 (5.6%) 16 (100.0%) 42 (77.8%) 14 (87.5%) 52 (96.3%)				

Values given as mean (SD) or frequency (%). Values marked with * are given as median (IQR).
Abbreviations: SBP; systolic blood pressure, DBP; diastolic blood pressure, MAP; mean arterial
pressure, WBC; white blood cell count, CRP; C-reactive protein, AST; aspartate transaminase, ALT;
alanine transaminase, INR; international normalized ratio, APTT; activated partial thromboplastin
time, RRT; renal replacement therapy, †PLEX; plasmapheresis, ‡DDAVP; desmopressin.

192

193 **Treatment modalities for LPHS**

194 Specific treatments received for LPHS were intravenous steroids, intranasal DDAVP (20µg, 6 hourly), and PLEX (60 mL/kg, using fresh frozen plasma, every other day), alone or in 195 196 combination. The steroids were given as intravenous methylprednisolone (500mg/day -197 1g/day) followed by oral prednisolone. The different steroid dosing regimens are given in supplementary table 1 (S1). The characteristics of the patients in the different treatment 198 groups are compared in Table 3. Patient characteristics and laboratory findings revealed that 199 200 the group who received PLEX alone had a significantly higher heart rate, lower systolic blood 201 pressure, higher serum lactate levels, and higher serum creatinine than the other groups. In 202 addition, a higher proportion in this group received fresh frozen plasma, cryoprecipitate, and

- 203 packed red cell transfusions. Other laboratory parameters were not significantly different in
- 204 the treatment groups.

Table 3: Comparison of patient characteristics, treatment, and outcomes between

206 treatment strategies for LPHS

207

		es				
Parameter	Total (n=70)	PLEX† alone (n=7)	PLEX† + DDAVP‡ (n=13)	PLEX† + DDAVP‡ + Steroids (n=46)	Steroids alone (n=4)	p- value

Clinical parameters at the time of admission to MICU

Heart rate (bpm)	104.0 (19.7)	117.3 (28.5)	87.2 (14.5)	106.4(17.4)	107.5 (14.4)	0.002
SBP (mmHg)	115.0 (24.5)	108.3 (22.6)	122.5 (21.0)	114.1 (26.5)	112.5 (12.6)	0.616
DBP (mmHg)	67.4 (13.3)	63.1 (7.4)	68.7 (9.1)	67.1 (15.1)	75.0 (9.1	0.546
MAP (mmHg)	83.3 (16.0)	78.2 (12.2)	86.6 (12.6)	82.8 (17.8)	87.5 (8.8)	0.666
WBC (x10³/µL) *	14.2 (9.5 - 18.4)	12.6 (11.8 - 17.1)	15.5 (11.0 - 23.3)	12.7 (7.8 - 9.2)	14.1 (10.0 - 25.3)	0.839
Haemoglobin (g/dL)	10.4 (2.2)	10.1 (2.7)	10.8 (1.5)	10.4 (2.4)	10.6 (1.3)	0.884
Platelet count (x10³/µL) *	32.0 (21.0 - 64.3)	51.0 (34.0 – 60.0)	23.0 (20.0 - 82.5)	32.0 (23.8 - 65.8)	19.0 (16.3 - 38.3)	0.378
CRP (mg/dL)	224.3 (88.3)	177.6 (48.8)	203.3 (75.9)	234.3 (92.5)	260.5 (112.5)	0.269
AST (U/L) *	89.5 (61.0 – 178.0)	101.0 (63 – 166)	79.0 (44.5 - 225.5)	90.5 (65.5 – 178)	76.5 (62.5 - 205.25)	0.881
ALT (U/L) *	51.0 (36.25 - 95.75)	45.0 (34.0 – 134.0)	45.0 (33.5 – 100.0)	53.0 (36.3 - 90.5)	49.5 (41.0 – 94.0)	0.964
INR*	1.1 (1.0 - 4.4)	1.0 (0.9 - 1.4)	1.1 (1.1 -1.4)	1.1 (1.0 -1.4)	1.3 (1.1 - 1.9)	0.485
APTT (seconds)*	34.4 (29.6 - 40.1)	33.0 (26.0 – 35.0)	38.0 (29.3 -42.3)	34.9 (29.6 - 40.1)	31.1 (29.3 - 41.9)	0.503
Serum creatinine (μmol/L)	356.7 (167.1)	428.6 (191.1)	331.8 (178.7)	361.1 (162.9)	261.3 (126.2)	0.411
Serum sodium (mmol/L) *	136.0 (132.7- 139)	135.0 (131.0 – 136.0)	136.0 (128- 140.5)	136.0 (133.0 – 139.0)	137.5 (133.3 - 140.3)	0.663

Serum potassium(mmol/L) *	4.0 (3.5 - 4.4)	4.3 (3.2 - 4.6)	3.6 (3.2 - 3.95)	4.0 (3.6 - 4.5)	4.3 (3.80 - 5.15)	0.12
pH	7.3 (0.1)	7.2 (0.2)	7.4 (0.1)	7.3 (0.1)	7.2 (0.2)	0.01
Base excess (mmol/L)	-7.3 (6.0)	-5.3 (5.7)	-5.5 (6.2)	-7.8 (6.0)	-10.7 (4.7)	0.32
Serum lactate (mmol/L) *	2.6 (1.6 - 4.3)	3.8 (1.4 - 5.3)	2.1 (1.15 -2.95)	2.6 (1.7 - 4.8)	2.6 (1.325 - 6.8)	0.50
Complications	11		1	I	I	1
Myocarditis	58 (82.9%)	4 (57.1%)	12 (92.3%)	39 (84.8%)	3 (75.0%)	0.22
Acute kidney injury	69 (98.6%)	7 (100.0%)	13 (100.0%)	45 (97.8%)	4 (100.0%)	0.91
Ancillary treatment						
Mechanical ventilation	49 (70.0%)	5 (71.4%)	6 (46.2%)	35 (76.1%)	3 (75.0%)	0.22
Tranexamic acid	5 (7.1%)	1 (14.3%)	0 (0.0%)	3 (6.5%)	1 (25.0%)	0.32
Renal replacement therapy	43 (61.4%)	4 (57.14%)	6 (46.2%)	32 (69.6%)	1 (25.0%)	0.18
Blood product transfu	sion					
Packed red cell transfusion	26 (37.1%)	4 (57.1%)	0 (0.0%)	21 (45.7%)	1 (25.0%)	0.01
Platelet transfusion	60 (85.7%)	6 (85.7%)	9 (69.2%)	43 (935%)	2 (50.0%)	0.02
Cryoprecipitate transfusion	3 (4.3%)	1 (14.3%)	0 (0.0%)	2 (4.4%)	0 (0.0%)	0.48
Fresh frozen plasma transfusion	8 (11.4%)	3 (42.9%)	0 (0.0%)	4 (8.7%)	1 (25.0%)	0.02
Outcome	1		1	I		1
Death at 32 days	16 (22.9%)	3 (42.9%)	0 (0.0%)	11 (23.9%)	2 (50.0%)	0.06
Duration of mechanical ventilation*/days	5 (3.0 - 8.0)	3 (2.0 - 8.5)	3 (2.5 - 4.5)	5 (4.0 - 8.5)	1 (1)	0.19
Duration of treatment in the ICU*/days	6 (3.0 - 11.0)	5 (3.0 - 6.0)	5 (3.0 - 10.5)	6 (4.0- 11.25)	2 (1.0 - 22.5)	0.24
Hospital-acquired	25	2	1	21	1	

208 Mean (SD) or frequency (%) used. Nonparametric distributions are indicated with * and given as

209 median (IQR). Abbreviations: PCR; Polymerase chain reaction, MAT; microscopic agglutination test,

210 SBP; systolic blood pressure, DBP; diastolic blood pressure, MAP; mean arterial pressure, WBC; white

211 blood cell count, CRP; C reactive protein, AST; aspartate transaminase, ALT; alanine transaminase, INR;

international normalized ration, APTT; activated partial thromboplastin time, RRT; renal replacement
 therapy, *PLEX*; plasmapheresis, *‡DDAVP*; desmopressin

214

215 All patients treated with the PLEX and DDAVP combination survived. Mortality was low in the 216 group treated with PLEX + DDAVP + steroids compared to PLEX alone or steroids alone. A 217 logistic regression and a univariate Cox regression analysis were performed to calculate the 218 odds and hazard ratios for death among different treatment modalities (Figure 1a) and 219 treatment combinations (Figure 1b) using the group treated with steroids as the reference 220 (Table 4). The odds ratio (OR) for the group that received PLEX + DDAVP without steroids 221 222 could not be calculated as the morality was 0%. Figure 1: Hazard regression plots for mortality in patients with LPHS. Cox regression 223 224 analysis was performed to analyze the effect of different treatments received by patients with LPHS on mortality. Patients were treated with plasmapheresis (PLEX), desmopressin 225 (DDAVP), and steroids alone or in different combinations. Hazard regression plots 226 227 demonstrate the risk of mortality (hazard ratio) and the confidence interval. (a) Patients who received each treatment modality were compared with patients who did not receive 228 the treatment. (b) Treatment combinations were compared with the group who received 229

- 230 steroids alone.
- 231

232 Table 4: Risk of mortality in patients with LPHS who received different treatment

233 combinations

Treatment	Total n=70	Mortality n (%)	OR (95% CI)	HR (95% CI)
PLEX alone	7	3 (42.9%)	0.75 (0.06 – 8.83)	0.65 (0.11 – 3.92)
PLEX + DDAVP	13	0 (0%)	NC	NC
PLEX + DDAVP + steroids	46	11 (23.9%)	0.31 (0.04 – 2.5)	0.29 (0.06 – 1.32)
Steroids alone	4	2 (50%)		

234 Abbreviations: OR; odds ratio, HR; Hazards ratio, NC; Not calculated

Transfusion of blood products and treatment with tranexamic acid did not meet statistical significance in the logistic regression analysis predictors of mortality. The Kaplan-Meier survival curves comparing the treatment combinations in patients with LPHS are given in Figure 2. All patients who were discharged to the ward after complete recovery were assumed to have survived till the end of follow up i.e.: 32 days (the maximum duration of ICU stay before death).

242

243 Figure 2: Kaplan-Meier survival curves of patients with LPHS who received different

244 treatment combinations. The figure shows the survival of patients with LPHS who received

plasmapheresis (PLEX) alone (n=7), PLEX and desmopressin (DDAVP) combination (n=13),

246 PLEX+DDAVP and steroids combination (n=46) or steroids alone (n=4).

247

248 A Cox regression analysis was performed to assess the relationship of the duration of PLEX 249 with mortality. Since PLEX for 1 day and 6 days were done only for 1 patient each, and PLEX for 2 days had only 2 patients, they were excluded from the analysis. The hazard ratios for 250 death were calculated for different durations of PLEX compared to the group who received 251 252 PLEX for three days. Hazard ratios were 2.46 (0.58-10.47, p>0.05) and 5.9 (1.13-30.95, p 253 0.04) in the groups who received PLEX for 4 days and 5 days respectively. Steroids (p=0.620) and DDAVP (p=0.430) were used equally among the groups who received different 254 durations of PLEX. The Kaplan-Meier survival curves comparing the duration of PLEX are 255 given in Figure 3. 256

257

Figure 3: Kaplan-Meier survival curves of patients with LPHS who received different durations of plasmapheresis (PLEX). Figure shows the survival of patients with LPHS who

received PLEX for 1 day (n=1), 2 days (n=2), 3 days (n=54), 4 days (n=8), 5 days (n=3) and 6
days (n=1).

262

263 Hospital-acquired infection (HAI) in the study population

264 HAI occurred in 25 (35.7%) patients. Respiratory tract infections (n=16, 61.5%) and catheterassociated bloodstream infections (n=2, 7.7%) were the common sources of HAIs. Logistic 265 regression analysis was performed to identify risk factors for the development of HAI. 266 267 Mechanical ventilation (OR 30.34, CI 1.55- 592.10) and duration of ICU stay (OR 1.37, CI 1.12-1.68) were risk factors for the development of HAI. A higher proportion of patients in the PLEX 268 + DDAVP+ steroid group developed HAI compared to the groups who received PLEX + DDAVP 269 combination or PLEX and steroids alone (Table 3). However, different treatment modalities 270 received by patients for LPHS (compared to receiving steroids alone), renal replacement 271 272 therapy, or blood product transfusion were not significantly associated with developing HAI in logistic regression analysis. 273

274

275 Discussion

LPHS is a dreaded complication of leptospirosis due to its high mortality and challenges in management. There is a paucity of data on the clinical characteristics and outcomes of LPHS. In this retrospective cohort study of a large number of LPHS patients, we report characteristics, risk factors for death, and outcomes from different treatment modalities for LPHS. This is the first study that compares the outcome of PLEX, DDAVP, and steroid treatment alone or in combination for LPHS. Findings from this study provide a platform to design future clinical trials.

283

Patients who developed LPHS requiring ICU care, had myocarditis (n=58, 82.9%), acute kidney 284 285 injury (n=69, 98.6%), and modest elevation in liver enzymes. A significant proportion required renal replacement therapy (n=43, 61.4%), mechanical ventilation (n=49, 70%), and blood 286 product transfusion (n=31, 44.3%). A previous Sri Lankan study reported a 35.4% mortality in 287 288 LPHS[21]. A mortality of 22.9% observed in this study is relatively lower than previous reports from Sri Lanka and other countries [22]. We found that demographic factors such as age and 289 gender were not significantly different in the patients who died compared to patients who 290 291 survived. However, tachycardia, lactataemia, and acidosis on admission to MICU were more common in the patients who died compared to the survivors. A higher proportion of patients 292 who succumbed to the illness were mechanically ventilated and received intravenous 293 tranexamic acid and fresh frozen plasma. This observation suggests that severe pulmonary 294 haemorrhage leading to respiratory failure and ongoing bleeding with coagulopathy would 295 296 have been present in this group.

297

Specific treatment for LPHS is controversial. Literature is scarce and any evidence supporting 298 steroids, PLEX, or DDAVP is based on case reports, observational studies, and expert opinion. 299 300 With the emergence of LPHS cases throughout the country, many centres in Sri Lanka use 301 PLEX as a therapeutic measure. Evidence for PLEX was based on the benefit observed in the treatment of pulmonary haemorrhage in autoimmune diseases such as Goodpasture's 302 syndrome, ANCA-associated vasculitis, systemic lupus erythematosus (SLE), and other 303 autoimmune reno-pulmonary syndromes [23–25]. The above diseases arise due to either 304 direct deposition of autoantibodies or antigen-antibody complexes in the alveolar-capillary 305 membrane, resulting in inflammation, pulmonary vasculitis, tissue damage, necrosis, and 306 307 pulmonary haemorrhage. Removal of auto-antibodies and circulating antigen-antibody

308 complexes provide the rationale for PLEX in the above conditions. As immune-mediated 309 damage is one theory for the pathogenesis of LPHS, it can be postulated that PLEX might be an effective therapy. In a previous study of 80 patients with LPHS at Teaching Hospital 310 Karapitiya Sri Lanka, 59 (73.75%) underwent PLEX of which 19 died (fatality rate; 32.2%) 311 312 compared to 17 (fatality rate; 89.5%) in the group which did not undergo PLEX [7]. Furthermore, the survival rate was higher (n = 35, 74.5%) when the PLEX was performed 313 within the first 48 hours compared to patients in whom the procedure was done after 314 315 48 hours (n = 5, 54.5%). PLEX was done for a mean duration of 3 consecutive days, using fresh frozen plasma. In an Indian study, a survival benefit was noted when two cycles of PLEX 24 316 hours apart were combined with IV cyclophosphamide, to treat LPH[26]. Numerous case 317 reports have described successful treatment of LPHS with PLEX, alone or in combination with 318 steroids, extra-corporeal membrane oxygenation [15,27-29]. All patients who received 319 320 PLEX+DDAVP survived. There was no statistically significant difference in the hazard ratio 321 between different treatment combinations of LPHS when the PLEX+DDAVP group was excluded from the analysis. The PLEX + DDAVP group was excluded as its mortality was zero. 322 However, survival curves demonstrated a favourable outcome in patients who received PLEX 323 + DDAVP combination than the other treatment groups. The PLEX alone group had higher 324 325 lactate and acidosis than the other groups on admission to MICU. As these parameters were predictors of mortality subsequently, the benefit of PLEX could have been masked by initial 326 severe LPHS in the group. The optimal duration of PLEX is either three or four days according 327 to the study findings. 328

Intravenous bolus doses of corticosteroids are used to treat pulmonary haemorrhages in auto-immune diseases. Using the same argument as for PLEX, corticosteroids have been used to treat LPHS. In the year 2008, Sri Lanka recorded a surge of leptospirosis cases with 7406

hospital admissions, 217 deaths, and a case fatality rate of 3%. Kularatne et al treated patients 332 333 with severe leptospirosis with intravenous methyl-prednisolone 500 mg for 3 days followed by 8 mg orally for 5 days. Treatment was compared to a historical cohort without steroid 334 treatment [30]. The outcome was analysed based on the organ dysfunction, co-morbidities, 335 336 and steroids significantly (p=0.012) reduced mortality in patients with LPHS. A mortality benefit was noted in the patients who received steroids in another study [31]. However, this 337 effect was seen only if the steroids were given within the first 12 hours. In an Australian study 338 339 describing the intensive care treatment for severe leptospirosis, IV hydrocortisone 200mg daily was used as a supportive measure [32]. There was no significant difference in the 340 incidence of pulmonary haemorrhage between the patients who did and did not receive 341 steroids. The mortality did not differ between the two groups. However, the patients treated 342 with steroids were sicker with a high APACHE III score and required more vasopressor 343 344 support. As per PLEX, numerous case reports describe successful management of LPHS with 345 high-dose bolus steroids. A concern of steroid treatment has been the increased incidence of HAIs. In our study, univariate analysis revealed that steroid treatment compared to no 346 steroids, increased mortality. This observation was not statistically significant on Cox 347 regression analysis. However, the addition of steroids to PLEX+DDAVP reduced survival 348 349 compared to PLEX+DDAVP alone. In addition, there was a non-significant increase of HAIs in steroid-treated groups compared to the PLEX+ DDAVP group. 350

351

Evidence for DDAVP in LPHS is limited. DDAVP releases endothelial haemostatic factors thereby, shortens prolonged bleeding times, and enhancing platelet adhesiveness to injured vessels[18] by activation and secretion of von Willebrand (vWF) factor from the endothelial cells. Leptospirosis is associated with bleeding beyond the lung ranging from petechiae,

ecchymoses, and epistaxis to massive gastro-intestinal bleeds. A platelet dysfunction is known 356 357 to occur in leptospirosis [33]. Furthermore, a coagulopathy associated with leptospirosis has been described. In an animal study, Leptospira infected hamsters had a prolonged PT, APTT, 358 and a thrombin time in all organ extracts, especially in the lung and the liver, probably due to 359 360 interference with the prothrombinase complex [34]. Platelet dysfunction, coagulopathy, and thrombocytopenia might be contributing to the increased bleeding observed in leptospirosis. 361 DDAVP might be acting by increasing the platelet activation and local production and 362 363 secretion of vWF and factor VIII. A theoretical risk of causing, aggravating disseminated intravascular coagulation is present with the use of DDAVP in severe leptospirosis. Pea et al 364 described six patients with LPHS treated with intravenous DDAVP [35]. Bleeding from the 365 endotracheal tube had reduced in intubated patients within one hour of DDAVP infusion, 366 despite repeated aspiration. An open randomized controlled trial of high-dose 367 368 dexamethasone and intravenous desmopressin alone or in combination did not alter the 369 outcome compared to placebo [16]. Intranasal DDAVP in LPHS has not been studied previously. Further studies are needed to explore its efficacy. In the interim, it can be stated 370 that DDAVP seems to be effective in combination with PLEX as a treatment for LPHS. 371

372

There was no statistically significant difference in mortality between different treatment groups when the PLEX+DDAVP group was excluded. However, our results demonstrate a clear survival benefit in PLEX+ DDAVP treatment compared to the addition of steroids, PLEX alone, or steroids alone. Reduced overall mortality in the study population compared to previous literature could also be due to the use of such therapeutic measures. Differences in the severity of the underlying disease could have played a role in interpreting the findings of this

study. As such, appropriately designed randomized controlled trials are urgently needed to
generate evidence and improve patient outcomes.

Patients who developed HAIs had a higher heart rate, INR, and a lower base excess. They were mechanically ventilated for a longer period, and treated with steroids and renal replacement therapy compared to the group that did not develop HAIs. Transfusion (FFP, RCC, platelet) rates were higher in the group that developed HAIs. However, only mechanical ventilation and duration of ICU stay were predictive of the development of HAI.

386

Treatment of LPHS is challenging due to the paucity of evidence. We have compared PLEX, 387 DDAVP, and the use of steroids in the management of LPHS alone or in combination. A major 388 389 limitation of this study is that the treatment was solely under the treating physician's discretion. Hence, the comparison between the treatment strategies is not ideal. Similarly, 390 391 the duration of PLEX and the steroid regimens used were not uniform. Furthermore, the 392 extent of lung involvement in LPHS has not been described or compared in this study and 393 poses a limitation in interpreting the results. However, the important observations of this cohort of large numbers of LPHS patients lay a foundation to conduct future studies and 394 randomized controlled trials. 395

396

397 Conclusions

Patients admitted with LPHS to an intensive care setting had renal, liver, and myocardial involvement requiring organ support, renal replacement therapy, and blood product transfusion. The presence of tachycardia, acidosis, and high lactate predicted death in LPHS. PLEX and DDAVP combination had better survival than other treatments alone or in

- combination for LPHS. Randomized clinical trials are urgently needed to identify the role of 402
- PLEX and DDAVP in treating LPHS. 403

404

405 Abbreviations

- 406 AKI – acute kidney injury
- DDAVP desmopressin 407
- FFP Fresh frozen plasma 408
- 409 HR – hazard ratio
- ICU intensive care unit 410
- LPHS Leptospirosis pulmonary haemorrhage syndrome 411
- MAT microscopic agglutination test 412
- 413 MICU – Medical intensive unit
- 414 NHSL – National Hospital of Sri Lanka
- 415 OR – odds ratio
- PCR polymerase chain reaction 416
- PLEX plasma exchange 417
- 418 RCC – Red cell concentrate
- 419 RRT – renal replacement therapy
- 420 ULN – upper limit of normal
- vWF von Willebrand factor 421

Acknowledgments 423

- 424 The authors would like to acknowledge the staff of MICU, National Hospital of Sri Lanka for
- 425 their assistance in conducting the study.
- 426

422

427 References

- 428 Rajapakse S. Leptospirosis: clinical aspects. Clinical Medicine. 2022;22: 14. 1.
- 429 doi:10.7861/CLINMED.2021-0784
- 430 2. Costa F, Hagan JE, Calcagno J, Kane M, Torgerson P, Martinez-Silveira MS, et al. Global 431 Morbidity and Mortality of Leptospirosis: A Systematic Review. PLoS Negl Trop Dis. 2015;9. 432 doi:10.1371/JOURNAL.PNTD.0003898
- 433 3. Cagliero J, Villanueva SYAM, Matsui M. Leptospirosis pathophysiology: Into the storm of 434 cytokines. Front Cell Infect Microbiol. 2018;8: 274770.
- doi:10.3389/FCIMB.2018.00204/BIBTEX 435
- 436 4. Carvalho CRR, Bethlem EP. Pulmonary complications of leptospirosis. Clin Chest Med. 2002;23: 469-478. doi:10.1016/S0272-5231(01)00010-7 437
- 438 5. Singh SS, Vijayachari P, Sinha A, Sugunan AP, Rasheed MA, Sehgal SC. Clinico-epidemiological 439 study of hospitalized cases of severe leptospirosis. Indian J Med Res. 1999;109: 94–99.
- 440 Marotto PCF, Nascimento CMR, Eluf-Neto J, Marotto MS, Andrade L, Sztajnbok J, et al. Acute 6. 441 lung injury in leptospirosis: clinical and laboratory features, outcome, and factors associated 442 with mortality. Clin Infect Dis. 1999;29: 1561-1563. doi:10.1086/313501
- Herath N, Uluwattage W, Weliwitiya T, Karunanayake L, Lekamwasam S, Ratnatunga N, et al. 443 7. 444 Sequel and therapeutic modalities of leptospirosis associated severe pulmonary
- 445 haemorrhagic syndrome (SPHS); A Sri Lankan experience. BMC Infect Dis. 2019;19: 1–8. 446 doi:10.1186/S12879-019-4094-0/TABLES/7

medRxiv preprint doi: https://doi.org/10.1101/2024.03.25.24304826; this version posted March 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

447 8. Fonseka CL, Dahanayake NJ, Mihiran DJD, Wijesinghe KM, Liyanage LN, Wickramasuriya HS, 448 et al. Pulmonary haemorrhage as a frequent cause of death among patients with severe 449 complicated Leptospirosis in Southern Sri Lanka. PLoS Negl Trop Dis. 2023;17: e0011352. 450 doi:10.1371/JOURNAL.PNTD.0011352 451 9. Luks AM, Lakshminarayanan S, Hirschmann J V. Leptospirosis presenting as diffuse alveolar 452 hemorrhage: case report and literature review. Chest. 2003;123: 639-643. 453 doi:10.1378/CHEST.123.2.639 454 Dolhnikoff M, Mauad T, Bethlem EP, Carvalho CRR. Pathology and pathophysiology of 10. 455 pulmonary manifestations in leptospirosis. Braz J Infect Dis. 2007;11: 142–148. doi:10.1590/S1413-86702007000100029 456 457 11. Nicodemo AC, Duarte MIS, Alves VAF, Takakura CFH, Santos RTM, Nicodemo EL. Lung lesions 458 in human leptospirosis: microscopic, immunohistochemical, and ultrastructural features 459 related to thrombocytopenia. Am J Trop Med Hyg. 1997;56: 181–187. 460 doi:10.4269/AJTMH.1997.56.181 461 12. Croda J, Neto AND, Brasil RA, Pagliari C, Nicodemo AC, Duarte MIS. Leptospirosis pulmonary 462 haemorrhage syndrome is associated with linear deposition of immunoglobulin and 463 complement on the alveolar surface. Clinical Microbiology and Infection. 2010;16: 593–599. 464 doi:10.1111/J.1469-0691.2009.02916.X 465 13. AREAN VM. The Pathologic Anatomy and Pathogenesis of Fatal Human Leptospirosis (Weil's 466 Disease). Am J Pathol. 1962;40: 393. 467 14. Reis EAG, Hagan JE, Ribeiro GS, Teixeira-Carvalho A, Martins-Filho OA, Montgomery RR, et al. Cytokine Response Signatures in Disease Progression and Development of Severe Clinical 468 469 Outcomes for Leptospirosis. PLoS Negl Trop Dis. 2013;7: e2457. 470 doi:10.1371/JOURNAL.PNTD.0002457 471 15. Chen HI, Kao SJ, Hsu YH. Pathophysiological mechanism of lung injury in patients with 472 leptospirosis. Pathology. 2007;39: 339–344. doi:10.1080/00313020701329740 473 Niwattayakul K, Kaewtasi S, Chueasuwanchai S, Hoontrakul S, Chareonwat S, Suttinont C, et 16. 474 al. An open randomized controlled trial of desmopressin and pulse dexamethasone as adjunct 475 therapy in patients with pulmonary involvement associated with severe leptospirosis. Clinical 476 Microbiology and Infection. 2010;16: 1207–1212. doi:10.1111/J.1469-0691.2009.03037.X 477 17. Pea L, Roda L, Boussaud V, Lonjon B. Desmopressin therapy for massive hemoptysis 478 associated with severe leptospirosis. Am J Respir Crit Care Med. 2003;167: 726–728. 479 doi:10.1164/RCCM.200205-450CR 480 18. Mannucci PM. Desmopressin (DDAVP) in the Treatment of Bleeding Disorders: The First 20 481 Years. Blood. 1997;90: 2515-2521. doi:10.1182/BLOOD.V90.7.2515 482 19. National Guidelines on Management of Leptospirosis Epidemiology Unit Ministry of Health, 483 Nutrition and Indigenous Medicine Sri Lanka. 2016. KDIGO Clinical Practice Guideline for Acute Kidney Injury. doi:10.1038/kisup.2012.1 484 20. 485 21. Fonseka CL, Dahanayake NJ, Mihiran DJD, Wijesinghe KM, Liyanage LN, Wickramasuriya HS, 486 et al. Pulmonary haemorrhage as a frequent cause of death among patients with severe 487 complicated Leptospirosis in Southern Sri Lanka. PLoS Negl Trop Dis. 2023;17. 488 doi:10.1371/JOURNAL.PNTD.0011352 Dolhnikoff M, Mauad T, Bethlem EP, Carvalho CRR. Pathology and pathophysiology of 489 22. 490 pulmonary manifestations in leptospirosis. Braz J Infect Dis. 2007;11: 142–148. doi:10.1590/S1413-86702007000100029 491 492 23. Simpson IJ, Doak PB, Williams LC, Blacklock HA, Hill RS, Teague CA, et al. Plasma exchange in 493 Goodpasture's syndrome. Am J Nephrol. 1982;2: 301-311. doi:10.1159/000166666 494 24. Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasmapheresis 495 Therapy for Diffuse Alveolar Hemorrhage in Patients with Small-Vessel Vasculitis. American 496 Journal of Kidney Diseases. 2003;42: 1149–1153. doi:10.1053/j.ajkd.2003.08.015

medRxiv preprint doi: https://doi.org/10.1101/2024.03.25.24304826; this version posted March 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

497 25. Abe Y, Kusaoi M, Tada K, Yamaji K, Tamura N. Efficacy of plasma exchange therapy for diffuse 498 alveolar hemorrhage in patients with microscopic polyangiitis. Therapeutic Apheresis and Dialysis. 2022;26: 515-521. doi:10.1111/1744-9987.13824 499 500 26. Trivedi S V, Vasava AH, Bhatia LC, Patel TC, Patel NK, Patel NT. Plasma exchange with 501 immunosuppression in pulmonary alveolar haemorrhage due to leptospirosis. Indian J Med 502 Res. 2010;131: 429-433. 503 27. Dursun B, Bostan F, Artac M, Varan HI, Suleymanlar G. Severe pulmonary haemorrhage 504 accompanying hepatorenal failure in fulminant leptospirosis. Int J Clin Pract. 2007;61: 164– 505 167. doi:10.1111/J.1742-1241.2005.00638.X 506 Chaikajornwat J, Rattanajiajaroen P, Srisawat N, Kawkitinarong K. Leptospirosis manifested 28. 507 with severe pulmonary haemorrhagic syndrome successfully treated with venovenous 508 extracorporeal membrane oxygenation. BMJ Case Rep. 2020;13. doi:10.1136/BCR-2019-509 230075 510 29. Kularathna MDSV, Kularatne SAM, Pathirage M, Nanayakkara PTMA. Severe leptospirosis 511 complicated with multiorgan dysfunction successfully managed with plasma exchange: a case 512 report. J Med Case Rep. 2021;15: 1–6. doi:10.1186/S13256-021-03135-3/TABLES/1 513 30. Kularatne SAM, Budagoda BDSS, de Alwis VKD, Wickramasinghe WMRS, Bandara JMRP, 514 Pathirage LPMMK, et al. High efficacy of bolus methylprednisolone in severe leptospirosis: a 515 descriptive study in Sri Lanka. Postgrad Med J. 2011;87: 13–17. 516 doi:10.1136/pgmj.2009.092734 517 31. Shenoy V V., Nagar VS, Chowdhury AA, Bhalgat PS, Juvale NI. Pulmonary leptospirosis: an excellent response to bolus methylprednisolone. Postgrad Med J. 2006;82: 602. 518 doi:10.1136/PGMJ.2005.044255 519 Smith S, Liu YH, Carter A, Kennedy BJ, Dermedgoglou A, Poulgrain SS, et al. Severe 520 32. 521 leptospirosis in tropical Australia: Optimising intensive care unit management to reduce 522 mortality. PLoS Negl Trop Dis. 2019;13: e0007929. doi:10.1371/JOURNAL.PNTD.0007929 523 33. Tunjungputri RN, Gasem MH, van der Does W, Sasongko PH, Isbandrio B, Urbanus RT, et al. 524 Platelet dysfunction contributes to bleeding complications in patients with probable 525 leptospirosis. PLoS Negl Trop Dis. 2017;11. doi:10.1371/JOURNAL.PNTD.0005915 526 34. Vieira ML, de Andrade SA, Morais ZM, Vasconcellos SA, Dagli MLZ, Nascimento ALTO. 527 Leptospira infection interferes with the prothrombinase complex assembly during 528 experimental leptospirosis. Front Microbiol. 2017;8: 248372. 529 doi:10.3389/FMICB.2017.00500/BIBTEX 530 35. Pea L, Roda L, Boussaud V, Lonjon B. Desmopressin Therapy for Massive Hemoptysis 531 Associated with Severe Leptospirosis. https://doi.org/101164/rccm200205-450CR. 2012;167: 532 726-728. doi:10.1164/RCCM.200205-450CR 533 Supporting information 534 535 S1 Table: Different regimens of steroids used to treat LPHS 536 537 Declarations 538 Ethics approval and consent to participate 539 540 541 Ethical approval was obtained from the Ethics Review Committee of the National Hospital of 542 Sri Lanka 543

544 **Consent for publication**

545

As this was a retrospective study using the patient's clinical details, consent was not obtained. All collected data were anonymised. Details that would point toward patient identification were not collected. Administrative approval from the Deputy Director of the National Hospital of Sri Lanka was obtained for the collection of anonymised patient details and publication in scientific journals.

551

552 Availability of data and materials

553 Data are available in the BioStudies database (https://www.ebi.ac.uk/biostudies/) under

accession number S-BSST1368.

555

556 **Competing interests**

557 The authors declare that they have no competing interests

558

559 Funding

560 This study did not receive any funding.

561





Figure 1



- Only PLEX
- PLEX + DDAVP
- PLEX + DDAVP+ Steroids
- Only Steroids

Figure 2




Figure 3